Clinical Trial Update: Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines [Phase 3]

View source ↗

Summary

Phase 3 trial comparing three lots of GSK DTaP-IPV candidate vaccine to DTaP + IPV vaccines; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• DTaP plus IPV vaccines
• DTaP-IPV Candidate Vaccine (diphtheria and tetanus toxoids and acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Acellular Pertussis | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05